Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients with Colorectal Carcinoma

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Zhang, Bin ^a   Wang, Zhijun ^b   Wu, Liangliang ^b   Zhang, Meng ^a   Li, Wei ^c   Ding, Jianhua ^a   Zhu, Jun ^a   Wei, Huafeng ^d   Zhao, Ke ^a  

^a Second Artillery General Hospital   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c THE AFFILIATED BRAIN HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD115 ANTIGEN; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; CD39 ANTIGEN; CD66B ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 4 RECEPTOR ALPHA; MICROSOMAL AMINOPEPTIDASE; PROGRAMMED DEATH 1 LIGAND 1; STEM CELL FACTOR RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CANCER STAGING; CIRCULATING MYELOID DERIVED SUPPRESSOR CELL; COLORECTAL CARCINOMA; COLORECTAL TUMOR; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR INFILTRATING MYELOID DERIVED SUPPRESSOR CELL; TUMOR VOLUME;

AGED; ANTIGENS, CD11B; ANTIGENS, SURFACE; COLORECTAL NEOPLASMS; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; MYELOID CELLS; NEOPLASM METASTASIS; NEOPLASM STAGING; SIALIC ACID BINDING IG-LIKE LECTIN 3;

EID: 84874236258     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057114     Document Type: Article

References (45)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, et al. (2005) Colorectal cancer. Lancet 365: 153-165.
2. Fearon ER Vogelstein B, (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
3. Vogelstein B, Kinzler KW, (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799.
4. Grivennikov SI, Greten FR, Karin M, (2010) Immunity, inflammation, and cancer. Cell 140: 883-899.
5. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436-444.
6. Schreiber RD, Old LJ, Smyth MJ, (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
7. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
8. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, et al. (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71: 1263-1271.
9. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V, (2012) Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology 12: 253-268.
10. Gabrilovich DI, Nagaraj S, (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology 9: 162-174.
11. Fujimura T, Mahnke K, Enk AH, (2010) Myeloid derived suppressor cells and their role in tolerance induction in cancer. Journal of Dermatological Science 59: 1-6.
12. Ostrand-Rosenberg S, (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunology, Immunotherapy 59: 1593-1600.
13. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, et al. (2010) Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor. Immunity 32: 790-802.
14. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, et al. (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118: 3367-3377.
15. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, et al. (2011) A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 118: 2254-2265.
16. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI, (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181: 5791-5802.
17. Younos IH, Dafferner AJ, Gulen D, Britton HC, Talmadge JE, (2012) Tumor regulation of myeloid-derived suppressor cell proliferation and trafficking. Int Immunopharmacol 13: 245-256.
18. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S, (2012) Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 35: 107-115.
19. Greten TF, Manns MP, Korangy F, (2011) Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 11: 802-807.
20. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, et al. (2009) Arginase I-Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes. Cancer Res 69: 1553-1560.
21. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, et al. (2008) A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135: 234-243.
22. Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, et al. (2010) Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate 70: 443-455.
23. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R, (2010) Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70: 4335-4345.
24. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, et al. (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203: 2691-2702.
25. Feng PH, Lee KY, Chang YL, Chan YF, Kuo LW, et al. (2012) CD14+S100A9+ Monocytic Myeloid-derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer. Am J Respir Crit Care Med 186: 1025-1036.
26. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, et al. (2008) Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14: 8270-8278.
27. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, et al. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58: 49-59.
28. Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, et al. (2012) Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat 132: 215-223.
29. Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, et al. (2011) Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 13: 591-599.
30. Duffy A, Zhao F, Haile L, Gamrekelashvili J, Fioravanti S, et al. (2012) Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunology, Immunotherapy.
31. Sun HL, Zhou X, Xue YF, Wang K, Shen YF, et al. (2012) Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol 18: 3303-3309.
32. Mundy-Bosse BL, Young GS, Bauer T, Binkley E, Bloomston M, et al. (2011) Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4(+) T cells from patients with GI malignancy. Cancer Immunol Immunother 60: 1269-1279.
33. Melani C, Chiodoni C, Forni G, Colombo MP, (2003) Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102: 2138-2145.
34. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, et al. (2000) Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 96: 3838-3846.
35. Ostrand-Rosenberg S, Sinha P, (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182: 4499-4506.
36. Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, et al. (2012) Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 130: 1109-1119.
37. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, et al. (2010) HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207: 2439-2453.
38. Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S, (2012) Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 61: 1155-1167.
39. Ghiringhelli F, Bruchard M, Chalmin F, Rebe C, (2012) Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol 2012: 473712.
40. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, et al. (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204: 1257-1265.
41. Bergamin LS, Braganhol E, Zanin RF, Edelweiss MI, Battastini AM, (2012) Ectonucleotidases in tumor cells and tumor-associated immune cells: an overview. J Biomed Biotechnol 2012: 959848.
42. Ryzhov S, Novitskiy SV, Goldstein AE, Biktasova A, Blackburn MR, et al. (2011) Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol 187: 6120-6129.
43. Zou W, Chen L, (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8: 467-477.
44. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, et al. (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65: 3044-3048.
45. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, et al. (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med.